Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Código QR

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis

Guardado en:

Detalles Bibliográficos
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3d8b4229da504d96a237401fa5b25a41
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
por: Maxwell Y. Lee, et al.
Publicado: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Shahram Salek-Ardakani, et al.
Publicado: (2021)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Corey Smith, et al.
Publicado: (2021)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2021)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Hong Chen, et al.
Publicado: (2021)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao M, et al.
Publicado: (2015)

Correction: TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
Publicado: (2021)

Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
por: Min Yu, et al.
Publicado: (2021)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea M, et al.
Publicado: (2021)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Yang Hu, et al.
Publicado: (2021)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Naoya Maekawa, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Federica Miglietta, et al.
Publicado: (2021)

Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
por: Sjoerd H van der Burg, et al.
Publicado: (2021)

Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Frank Riemer, et al.
Publicado: (2021)

Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy
por: James Harber, et al.
Publicado: (2021)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Min Li, et al.
Publicado: (2021)

Correction to: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
por: Chunfeng Xie, et al.
Publicado: (2021)

Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
por: Dobrin Draganov, et al.
Publicado: (2021)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Guru Sonpavde, et al.
Publicado: (2021)

Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade
por: Chisato Ohe, et al.
Publicado: (2021)

Correction: In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis
Publicado: (2021)

TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
por: Michael Conroy, et al.
Publicado: (2021)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Pascale Lejeune, et al.
Publicado: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Shunichi Taki, et al.
Publicado: (2021)

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
por: Mariaelena Pierobon, et al.
Publicado: (2021)

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Robert A. Szczepaniak Sloane, et al.
Publicado: (2021)

Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Publicado: (2021)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: Federica Cappuccini, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Qing Li, et al.
Publicado: (2021)

Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment
por: Naixue Yang, et al.
Publicado: (2021)

How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies
por: Xinran Wang, et al.
Publicado: (2021)

MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas
por: Zheng Zhao, et al.
Publicado: (2021)

Correction to: Co-relation with novel phosphorylation sites of IκBα and necroptosis in breast cancer cells
por: Sung Hoon Choi, et al.
Publicado: (2021)

Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
por: Jia Chen, et al.
Publicado: (2021)

Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor
por: Sumanth Nagabushan, et al.
Publicado: (2021)

Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy
por: Sung Uk Lee MD, et al.
Publicado: (2021)

Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Publicado: (2021)